Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19 - FDA.gov

• Respected FDA GMP online training courses and programs by SkillsPlus International Inc. 

According to the article:

The "U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Paxlovid is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset."

Read the full source article: Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19 - FDA.gov

Poor Oral and Periodontal Health a Risk For Erectile Dysfunction?!

An interesting read reported in this Medical News Today article, Erectile Dysfunction Might Be Associated With Chronic Periodontal Disease: Two Ends Of The Cardiovascular Spectrum. This is some early research suggesting that chronic periodontal disesase (CPD) might cause or be associated with erectile dysfuntion (ED) and/or coronary artery disease. In short, "CPD might be associated first with ED in young men and later with coronary artery disease in middle-aged men." It just might be time to recommit to better brushing, flossing, rinsing, etc. 

Return Home: http://drughealth.blogspot.com/